Jörg Lukas, Helbling Arthur, Yerly Daniel, Pichler Werner J
Department of Rheumatology, Immunology and Allergology, Inselspital, Bern University Hospital, University of Bern, 3010, Bern, Switzerland.
ADR-AC GmbH, Adverse Drug Reactions, Analysis and Consulting, Bern, Switzerland.
Clin Transl Allergy. 2020 Nov 23;10(1):52. doi: 10.1186/s13601-020-00359-2.
A drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe T cell mediated hypersensitivity reaction. Relapses of symptoms in the recovery phase are frequent and linked to the reduction of the corticosteroid treatment, to viral reactivations or to the exposure to new drugs. Here, we analyzed, how often the exposure to new drugs leads to new sensitization or drug-related relapses without detectable sensitization.
46 patients with DRESS treated in the allergy division of the Inselspital, Bern University Hospital, were retrospectively assessed. Drug-related relapses were analyzed in terms of frequency and whether a possible sensitization evaluated by skin tests and/or lymphocyte transformation tests (LTT) to the new drugs was detectable. Furthermore, drug tolerance was evaluated in a subset of patients.
56 relapses were observed in 27 of 46 patients with DRESS (58.7%). 33 (58.9%) of these relapses were associated with the use of new drugs, 30 drug-related relapses were evaluated by patch test and/or lymphocyte transformation test. In 8/30 (26.7%) drug-related relapses, a sensitization to the new drug was demonstrated, suggesting the emergence of a multiple drug hypersensitivity syndrome (MDH). 14 patients experienced 22 drug-related relapses without any detectable sensitization and only 1/6 patients developed new symptoms upon reexposure.
Patients with DRESS frequently suffered from drug related relapses. Half of the patients with drug-related relapses developed a MDH with proven sensitizations not only to the DRESS inducing drugs, but also to newly applied drugs. When not sensitized, drugs involved in drug related relapses could be reintroduced, if needed. Here, we propose a procedure for drug testing and future management of drug-related relapses in DRESS.
药物超敏反应伴嗜酸性粒细胞增多和全身症状(DRESS)是一种严重的T细胞介导的超敏反应。恢复阶段症状复发很常见,与皮质类固醇治疗的减少、病毒再激活或接触新药有关。在此,我们分析了接触新药导致新的致敏或无明显致敏的药物相关复发的频率。
对在伯尔尼大学医院因塞尔医院过敏科接受治疗的46例DRESS患者进行回顾性评估。从频率以及通过皮肤试验和/或淋巴细胞转化试验(LTT)评估对新药是否可能致敏的角度分析药物相关复发情况。此外,对一部分患者评估了药物耐受性。
46例DRESS患者中有27例(58.7%)出现了56次复发。其中33次复发(58.9%)与使用新药有关,30次药物相关复发通过斑贴试验和/或淋巴细胞转化试验进行评估。在30次药物相关复发中有8次(26.7%)显示对新药致敏,提示出现了多药超敏综合征(MDH)。14例患者经历了22次无任何明显致敏的药物相关复发,再次接触时只有1/6的患者出现了新症状。
DRESS患者经常出现药物相关复发。一半的药物相关复发患者出现了MDH,不仅对诱发DRESS的药物致敏,对新应用的药物也致敏。在未致敏的情况下,如果需要,参与药物相关复发的药物可以重新使用。在此,我们提出了一种DRESS患者药物检测及未来药物相关复发管理的程序。